Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision: v3.4.1 is now shown on the page, replacing the previous v3.4.0. This is a minor site update and does not modify any study details or eligibility criteria.SummaryDifference0.0%

- Check33 days agoChange DetectedUI text updates: Show glossary and Hide glossary options have been added, QC-related labels updated to 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', and the 'No FEAR Act Data' wording adjusted. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check41 days agoChange DetectedRevision: v3.3.4 has been added to the page. The previous Revision: v3.3.3 has been removed.SummaryDifference0.1%

- Check69 days agoChange DetectedLocations section updated to group sites under a centralized 'Locations' heading and to include Kentucky. The former 'Kentucky Locations' subsection has been removed.SummaryDifference0.2%

- Check90 days agoChange DetectedThe Publications section now states that items are automatically filled from PubMed and may not be about the study. Revision tag updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.